The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis

Carla Noemí Olivares, Carla Olivares, Olivares C, Analía Gabriela Ricci, Analía Ricci, Mariela Bilotas, Barañao RI, Rosa Inés Barañao, Gabriela Meresman
Fertility and sterility · 2011 · vol. 96(2) , pp. 428–433 · doi:10.1016/j.fertnstert.2011.05.063 · PMID:21683949 · W2111680823
Lab / animal OA: bronze CC0 ⤵ 57 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This paper investigated the inhibitory effects of celecoxib and rosiglitazone on experimental endometriosis, observing their impact on the condition.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate the effects of celecoxib and rosiglitazone on the implantation and growth of endometriotic-like lesions in a murine model of endometriosis. DESIGN: Prospective experimental study. SETTING: Animal research and laboratory facility. ANIMAL(S): Two-month-old female BALB/c mice. INTERVENTION(S): Surgically induced endometriosis in female BALB/C mice; 28 days of treatment with celecoxib, rosiglitazone, or their combination; counting, measuring, excising, and fixing lesions. MAIN OUTCOME MEASURE(S): Immunohistochemical examination for proliferating cell nuclear antigen (PCNA), CD31, and CD34 to assess cell proliferation and vascularization, with the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) technique for apoptosis evaluation. RESULT(S): Celecoxib and the combined treatment (celecoxib and rosiglitazone) statistically significantly reduced the mean number of lesions established per mouse, and all treatments diminished the implant volume. In addition, cell proliferation within the implants was statistically significantly reduced, and apoptosis was statistically significantly enhanced by all treatments. Also, we found that all treatments diminished the vascularized area in the lesion. CONCLUSION(S): These results are promising and reveal that celecoxib and rosiglitazone, combined or separately, have a beneficial effect on overall endometriotic growth.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Cyclooxygenase 2 Inhibitors Endometriosis Pyrazoles Sulfonamides Thiazolidinediones Analysis of Variance Analysis of Variance Animals Animals Antigens, CD34 Antigens, CD34 Antigens, CD34 Apoptosis Apoptosis Apoptosis Celecoxib Celecoxib Cell Proliferation Cell Proliferation Cell Proliferation

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (56)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-13T06:10:10.580696+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:09:02.791371+00:00
License: CC0 · commercial use OK